OICR spins offs to develop promising technologies

Guest Contributor
May 24, 2011

The Ontario Institute for Cancer Research (OICR) has spun off three companies to move anticancer technologies to market. The undisclosed investments follow seed funding provided through its Intellectual Property Development and Commercialization program. The new companies are: DLVR Therapeutics Inc, which is developing a nanoparticle delivery system for anticancer therapies; Harmonic Medical Inc, which uses image-guided ultrasound surgery technologies to target and destroy targeted cancer sites; and, TORCell Therapeutics Inc, which uses proprietary immunotherapy to treat acute myeloid leukemia….


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.